21.89 USD
↘ 0.09 (0.41%)AT CLOSE (03:59 PM EST)
Replimune Group, Inc.
REPLNASDAQ • USD
21.79
↘ 0.10 (0.45%)
POST MARKET (AS OF 04:14 PM EST)
Post Market
AS OF 04:14 PM EST
21.79
↘ 0.10 (0.45%)
Market: CLOSED
REPL is currently priced at $21.89. REPL shows a split signal: technical indicators suggest "Strong Buy" while underlying fundamentals indicate "Sell". This is driven by a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, negative Return on Equity, a bullish Golden Cross on the moving averages and bullish moving average alignment. On the valuation front, REPL trades at elevated multiples relative to its peers, earning a "Richly Valued" assessment.
Technical & fundamental data as of Nov 13, 2026.
Open?$21.78
High?$22.17
Low?$20.78
Prev. Close?$21.98
Volume?2.0M
Avg. Volume?2.9M
VWAP?$21.73
Rel. Volume?0.70x
Bid / Ask
Bid?$21.81 × 200
Ask?$21.89 × 200
Spread?$0.08
Midpoint?$21.85
Valuation & Ratios
Market Cap?2.1B
Shares Out?94.8M
Float?78.3M
Float %?83.5%
P/E Ratio?N/A
P/B Ratio?10.13
EPS?-$2.86
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Replimune Group Inc is a clinical-stage biotechnology company committed to applying its expertise in the field of oncolytic immunotherapy to transform the lives of cancer patients through novel oncolytic immunotherapies. Its proprietary oncolytic immunotherapy product candidates are designed and intended to maximally activate the immune system against cancer. Oncolytic immunotherapy is an emerging drug class. The proprietary RPx platform is based on a novel, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added that are intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. It operates in single segment of developing oncolytic immunotherapies for the treatment of cancer.
Employees
465
Market Cap
2.1B
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Website
Listed
2018-07-20
Address
500 UNICORN PARK
WOBURN, MA 01801
Phone: (781) 222-9600
WOBURN, MA 01801
Phone: (781) 222-9600
Technical OutlookStrong Buy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+2/3)
Medium-Term (Wave)?▲ Bullish(+2/3)
Short-Term (Ripple)?– Neutral(0/3)
MA Alignment?Golden Alignment
Full Technical Analysis →Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?3
Z-Score?7
Momentum?65
Short Sent.?31
Piotroski F-Score?0/9Weak
Altman Z-Score?0.67Distress
Confidence?59%Low
Short InterestSqueeze Risk
Short % of Float?31.43%Squeeze Risk
Short Interest?24.6M
Days to Cover?8.3
Free Float78.3M
Avg Daily Volume3.0M
Settlement Date2026-10-30
Financial Health
Current Ratio?7.11Strong
Quick Ratio?6.90Strong
Cash Ratio?6.76Strong
Debt/Equity?0.61Moderate
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score67/100
P/E?N/A▾
P/B?10.13HIGH▾
Peers100
S&P19
P/S?N/A▾
P/FCF?N/A▾
EV/EBITDA?-7.2CHEAP▾
S&P97
EV/Sales?N/A▾
Returns & Efficiency
ROE?-132.4%WEAK▾
S&P3
ROA?-72.5%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$-245769000
Enterprise Value?$1.9B
Fundamentals ratios updated end of day